This Article Full Text Full Text (PDF) Perspective on this Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Papadimitrakopoulou, V. Articles by Hong, W. K. Search for Related Content PubMed PubMed Citation Articles by Papadimitrakopoulou, V. Articles by Hong, W. K. Related Collections Clinical Intervention Clinical Intervention: Early-Phase (I/II) Clinical or Translational Trials Clinical Intervention: Biomarkers Risk Assessment: Biomarkers Commentary

Cyclin D1 and Cancer Development in Laryngeal Premalignancy Patients

Authors' Affiliations: Departments of ¹ Thoracic/Head and Neck Medical Oncology, ² Experimental Therapeutics, ³ Biostatistics, ⁴ Head and Neck Surgery, ⁵ Pathology, and ⁶ Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Vassiliki Papadimitrakopoulou, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 432, Houston, TX 77030. Phone: 713-792-6363; Fax: 713-792-1220; E-mail: vpapadim{at}mdanderson.org or Julie G. Izzo, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 432, Houston, TX 77030. E-mail: jizzo{at}mdanderson.org.

In a previous trial, we found that combined 13-cis-retinoic acid, IFN-, and -tocopherol more effectively reversed advanced premalignant lesions of the larynx than of the oral cavity and that cyclin D1 (CD1) G/A870 single nucleotide polymorphism correlated with cancer risk. We conducted the present trial primarily to confirm the clinical activity of the combination in advanced laryngeal premalignancy and to confirm and extend our findings on CD1, both genotype and protein expression, in association with cancer risk in this setting. Twenty-seven moderate-to-severe laryngeal dysplasia patients underwent induction with combined 13-cis-retinoic acid daily, -IFN twice weekly, and -tocopherol daily for 1 year; 14 nonprogressing patients then were randomized to maintenance fenretinide or placebo for 2 years. During induction, two patients had pathologic complete responses, six had partial responses (30% overall response rate), and five developed laryngeal cancer. There were no significant differences between maintenance fenretinide and placebo in response or cancer rates. Ten patients developed cancer overall. Twenty-four patients were evaluated for the CD1 G/A870 genotype, and 23 for pretreatment and posttreatment CD1 protein expression. Consistent with our earlier report, shorter cancer-free survival was associated with the CD1 AA/AG genotype (P = 0.05). Extending our earlier work, high CD1 expression was associated with worse cancer-free survival overall (P = 0.04) and within each CD1 genotype group. These findings support CD1 genotype and protein expression as important risk markers for laryngeal cancer and suggest future trials targeting upstream regulators of CD1 transcription.

Key Words: Premalignant lesions • larynx • biochemoprevention • cyclin D1 genotype • cyclin D1 protein expression

Commentary

Retinoid Chemoprevention Trials: Cyclin D1 in the Crosshairs

Sarah J. Freemantle, Yongli Guo, and Ethan Dmitrovsky
Cancer Prevention Research 2009 2: 3-6. [Full Text] [PDF]

This article has been cited by other articles:

				A. S. Tsao, D. Liu, J. Martin, X.-m. Tang, J. J. Lee, A. K. El-Naggar, I. Wistuba, K. S. Culotta, L. Mao, A. Gillenwater, et al. Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions Cancer Prevention Research, November 1, 2009; 2(11): 931 - 941. [Abstract] [Full Text] [PDF]

				S. J. Freemantle, Y. Guo, and E. Dmitrovsky Retinoid Chemoprevention Trials: Cyclin D1 in the Crosshairs Cancer Prevention Research, January 1, 2009; 2(1): 3 - 6. [Full Text] [PDF]